Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
40 participants
INTERVENTIONAL
2011-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
At each study site, 20 subjects will be enrolled. Each subject will attend the study centre in a fasting state, for a screening visit, 2 study visits (one baseline and one end of treatment), 1 intermediate safety visit and 1 post-study follow-up visit (Total 5 visits). The subjects at each site will be randomized to receive TRC150094 or placebo in a ratio of 1:1. 50 mg dose will be administered once daily (morning) under fasting conditions. Dosing will take place daily on Days 1-28. Subjects will arrive at the study centre for screening visit. Physical examination, vital signs, safety biochemistry and laboratory investigations for verification of inclusion/ exclusion criteria will be performed during screening visit. Subjects meeting all the inclusion criteria and none of the exclusion criteria and who have given their informed consent for the study will be asked to come for the study on Day 0 (or day -1 if required). Baseline investigations (including baseline clamp procedure and hepatic MRS) will be done on Day 0 (or day -1). Subjects will receive properly labelled bottle containing either Active treatment or Placebo as per the randomization number of the subject.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo
Tablets once daily
TRC150094
TRC150094
50 mg Tablets once a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TRC150094
50 mg Tablets once a day
Placebo
Tablets once daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Adult male
2. Age range 30-65 years at screening
3. Caucasian or Indian ethnicity
4. Waist circumference ≥ 102 cm for Caucasians and ≥ 90 cm for Indians at screening.
5. Fasting Serum Insulin ≥ 10 mU/ml at screening
6. Blood Pressure ≥ 130/85 mmHg at screening (or patients taking medication for hypertension)
7. Stable weight during 3 months prior to the study (assessed through medical history of the patient)
8. Drug naive diabetic patients\* or patients with impaired fasting glucose i.e \> 100 mg/dl or 5.5 mmol/l and \< 200 mg/dl or 11.0 mmol/l Diabetic patients who were taking metformin and have undergone washout for at least 4 weeks before Day 0 and are currently on life style modification as a treatment for diabetes will also be allowed in the study
9. Willingness to give written informed consent (prior to any study-related procedures being performed) and ability to adhere to the study restrictions and assessments schedule.
* Diabetic patient is defined as a patient with a documented history of type II DM or a documented history of a fasting glucose \> 200mg/dl or 11.0 mmol/l or 2x fasting glucose \> 126 mg/dl or 6.9 mmol/l (2x =recorded twice).
Exclusion Criteria
1. Medical history, physical examination, vital signs, clinical laboratory tests, 12-lead ECG and Chest X ray (to exclude tuberculosis in India only) with any significant abnormalities, in the opinion of the investigator.
2. Subjects with any known somatic illness, including neoplasm, endocrine disorder such as cushing's disease, PCOD and uncontrolled hypothyroidism, neurologic disorder, active infection, or recent surgical procedure within 3 months of the study initiation.
3. Subject currently using medication, which can influence glucose or FFA metabolism such as fibrates, niacin, ACE inhibitors, PPAR agonists, omega 3 fatty acids.
4. eGFR \< 60 mL/min/1.73m2 at screening as evaluated by Modification of Diet in Renal Disease (MDRD) method.
5. History of angina, Myocardial Infarction (MI) or stroke since last 6 months.
6. Hypertension with SBP/DBP ≥160/100 mmHg at screening.
7. ALT or AST ≥ ULN\*3 at screening
8. History or presence of malignancy.
9. History of recreational drug use within the last 30 days, or regular consumption of greater than 2 units of alcohol/day.
10. History of allergy to the test drug or any drug chemically similar to the drug under investigation.
11. Seropositive for Hepatitis B, Hepatitis C or HIV.
12. Subjects suffering from any psychiatric (acute or chronic) illness.
13. Intake of any medication except those permitted in this study (see Section 6.6).
14. Intake of any investigational drug in the period within 3 months prior to the first dose of study drug.
15. History of significant blood loss due to any reason, including blood donation, in the 12 weeks prior to the first dose of study drug; or the total blood loss in the last 3 months, including for this study, exceeds 450 mL.
16. History of any bleeding disorder.
17. Existence of any surgical or medical condition which, in the judgment of the principal investigator, might interfere with the absorption, distribution, metabolism or excretion of the study drug or might be likely to compromise the safety of the subject.
18. Inability to communicate or co-operate with the investigator because of language problems, poor mental development or impaired cerebral function.
19. Inability to comply with study requirements.
20. Positive drugs of abuse test (at screening) and alcohol breath test.
21. Heavy smokers (who are smoking \>15 cigarettes or equivalent per day).
30 Years
65 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Torrent Pharmaceuticals Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Erik Stroes, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Vascular Medicine, AMC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Academic Medical Centre,
Amsterdam, Amsterdam, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Zambad SP, Munshi S, Dubey A, Gupta R, Busiello RA, Lanni A, Goglia F, Gupta RC, Chauthaiwale V, Dutt C. TRC150094 attenuates progression of nontraditional cardiovascular risk factors associated with obesity and type 2 diabetes in obese ZSF1 rats. Diabetes Metab Syndr Obes. 2011 Jan 6;4:5-16. doi: 10.2147/DMSOTT.S15323.
Cioffi F, Zambad SP, Chhipa L, Senese R, Busiello RA, Tuli D, Munshi S, Moreno M, Lombardi A, Gupta RC, Chauthaiwale V, Dutt C, de Lange P, Silvestri E, Lanni A, Goglia F. TRC150094, a novel functional analog of iodothyronines, reduces adiposity by increasing energy expenditure and fatty acid oxidation in rats receiving a high-fat diet. FASEB J. 2010 Sep;24(9):3451-61. doi: 10.1096/fj.10-157115. Epub 2010 May 7.
van der Valk F, Hassing C, Visser M, Thakkar P, Mohanan A, Pathak K, Dutt C, Chauthaiwale V, Ackermans M, Nederveen A, Serlie M, Nieuwdorp M, Stroes E. The effect of a diiodothyronine mimetic on insulin sensitivity in male cardiometabolic patients: a double-blind randomized controlled trial. PLoS One. 2014 Feb 21;9(2):e86890. doi: 10.1371/journal.pone.0086890. eCollection 2014.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-002398-42
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CT/P015/CMR/2010/02_01
Identifier Type: -
Identifier Source: org_study_id